U.S. markets closed

RedHill Biopharma Ltd. (RDHL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.23-0.27 (-2.84%)
At close: 4:00PM EST

8.23 -1.00 (-10.83%)
After hours: 5:59PM EST

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close9.50
Open9.82
Bid8.31 x 800
Ask9.15 x 800
Day's Range9.10 - 9.93
52 Week Range3.26 - 11.52
Volume511,112
Avg. Volume506,730
Market Cap383.847M
Beta (5Y Monthly)1.62
PE Ratio (TTM)N/A
EPS (TTM)-1.80
Earnings DateNov 12, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares
    PR Newswire

    RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 1,250,000 American Depositary Shares (ADSs) of the Company, at a price to the public of $8.00 per ADS, less underwriting discounts and commissions. Each ADS represents ten ordinary shares, par value NIS 0.01 per share, of the Company. The closing of the offering is expected to occur on or about March 4, 2021, subject to satisfaction of customary closing conditions.

  • Benzinga

    RedHill Biopharma Expands Opaganib Global COVID-19 Study To US

    Following the FDA review of data from the U.S. Phase 2 study of opaganib and receipt of its recommendations, RedHill Biopharma Ltd (NASDAQ: RDHL) plans to expand its global Phase 2/3 study of opaganib in patients with severe COVID-19 to the U.S. The study's expansion to the U.S. will help further speed-up enrollment, expand the study to eight countries and approximately 40 recruiting sites. The 464-patient study is over 50% enrolled, and topline data expected in the second quarter of 2021. The global Phase 2/3 study recently underwent a positive DSMB futility review, which is suggestive that the study has the potential for a positive outcome. In December last year, the company announced positive topline data from the non-powered U.S. Phase 2 study with opaganib in patients with COVID-19 pneumonia and demonstrated positive safety and efficacy signals. Opaganib is an orally-administered sphingosine kinase-2 (SK2) inhibitor with demonstrated antiviral, anti-inflammatory, and anti-thrombotic activity that targets a human cell component involved in viral replication. Price Action: RDHL shares are down 3.0397% at $10.95 in the premarket trading on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaRedHill Biopharma, Cosmo Pharma In Manufacturing Pact for Movantik, RHB-204© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.
    PR Newswire

    RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced its plans to expand the Company's global Phase 2/3 study of opaganib[1] in patients with severe COVID-19 to the U.S., following U.S. Food and Drug Administration (FDA) review of the data from the U.S. Phase 2 study of opaganib and receipt of its recommendations.